BML Capital Management
Latest statistics and disclosures from BML Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SGOV, TIL, AVIR, ACRS, BIL, and represent 61.48% of BML Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ANTX (+$6.2M), AADI, ACHL, ADVM, ORMP, ACRS, RPHM, AVIR, PIRS, PMVP.
- Started 5 new stock positions in AADI, HLVX, PIRS, Forte Biosciences, ANTX.
- Reduced shares in these 10 stocks: TECX (-$7.7M), TIL, WING, ATHA, BIL, DSGN, FBRX, VNDA, LENZ, CALC.
- Sold out of its positions in ATHA, DSGN, FBRX, WING.
- BML Capital Management was a net buyer of stock by $1.1M.
- BML Capital Management has $170M in assets under management (AUM), dropping by 21.28%.
- Central Index Key (CIK): 0001616824
Tip: Access up to 7 years of quarterly data
Positions held by BML Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for BML Capital Management
BML Capital Management holds 29 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ishares Tr 0-3 Mnth Treasry (SGOV) | 16.0 | $27M | 270k | 100.72 |
|
|
| Instil Bio Com New (TIL) | 13.3 | $23M | -14% | 335k | 67.32 |
|
| Atea Pharmaceuticals (AVIR) | 13.1 | $22M | +4% | 6.7M | 3.35 |
|
| Aclaris Therapeutics (ACRS) | 9.6 | $16M | +9% | 14M | 1.15 |
|
| Spdr Ser Tr Bloomberg 1-3 Mo (BIL) | 9.5 | $16M | -12% | 175k | 91.81 |
|
| Adverum Biotechnologies Com New (ADVM) | 9.4 | $16M | +15% | 2.3M | 7.02 |
|
| Tectonic Therapeutic (TECX) | 3.8 | $6.4M | -54% | 212k | 30.30 |
|
| An2 Therapeutics (ANTX) | 3.6 | $6.2M | NEW | 5.7M | 1.07 |
|
| Reneo Pharmaceuticals (RPHM) | 3.5 | $5.9M | +29% | 3.5M | 1.70 |
|
| Oramed Pharmaceuticals Com New (ORMP) | 3.1 | $5.3M | +62% | 2.2M | 2.44 |
|
| Achilles Therapeutics Sponsored Ads (ACHL) | 2.5 | $4.2M | +555% | 4.1M | 1.02 |
|
| Aadi Bioscience (AADI) | 2.4 | $4.1M | NEW | 2.0M | 2.06 |
|
| Connect Biopharma Hldgs Ads (CNTB) | 1.8 | $3.0M | +2% | 2.1M | 1.44 |
|
| Pmv Pharmaceuticals (PMVP) | 1.5 | $2.5M | +28% | 1.7M | 1.49 |
|
| Astrotech Corp (ASTC) | 1.0 | $1.8M | 220k | 7.99 |
|
|
| Milestone Pharmaceuticals (MIST) | 1.0 | $1.7M | +3% | 1.1M | 1.52 |
|
| Lenz Therapeutics (LENZ) | 0.8 | $1.4M | -6% | 60k | 23.74 |
|
| Ikena Oncology (IKNA) | 0.7 | $1.3M | +23% | 723k | 1.73 |
|
| Vanda Pharmaceuticals (VNDA) | 0.6 | $1.1M | -42% | 229k | 4.69 |
|
| Lisata Therapeutics (LSTA) | 0.5 | $854k | 285k | 3.00 |
|
|
| Pieris Pharmaceuticals Com New (PIRS) | 0.4 | $699k | NEW | 42k | 16.58 |
|
| Calcimedica Com New (CALC) | 0.4 | $682k | -4% | 154k | 4.43 |
|
| Allovir (ALVR) | 0.3 | $488k | 603k | 0.81 |
|
|
| Talis Biomedical Corp Com New (TLIS) | 0.3 | $460k | +481% | 249k | 1.85 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.3 | $452k | 150k | 3.01 |
|
|
| Forte Biosciences Com New | 0.2 | $394k | NEW | 71k | 5.59 |
|
| Nextcure (NXTC) | 0.2 | $379k | 277k | 1.37 |
|
|
| Verrica Pharmaceuticals (VRCA) | 0.2 | $261k | 180k | 1.45 |
|
|
| Hillevax (HLVX) | 0.0 | $35k | NEW | 20k | 1.76 |
|
Past Filings by BML Capital Management
SEC 13F filings are viewable for BML Capital Management going back to 2022
- BML Capital Management 2024 Q3 filed Nov. 5, 2024
- BML Capital Management 2024 Q2 filed Aug. 7, 2024
- BML Capital Management 2024 Q1 restated filed April 24, 2024
- BML Capital Management 2024 Q1 filed April 23, 2024
- BML Capital Management 2023 Q4 restated filed Feb. 2, 2024
- BML Capital Management 2023 Q4 filed Jan. 30, 2024
- BML Capital Management 2023 Q3 filed Oct. 23, 2023
- BML Capital Management 2023 Q2 filed July 24, 2023
- BML Capital Management 2023 Q1 filed April 14, 2023
- BML Capital Management 2022 Q4 filed Feb. 13, 2023